Gerresheimer at the PDA Parenteral Packaging Conference in Phoenix Arizona
28 March 2012 | By Gerresheimer AG
Gerresheimer will display its comprehensive range of tubular glass...
List view / Grid view
News
Agreement to develop diagnostic assays for Alzheimer’s disease
28 March 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Meso Scale Discovery have entered an agreement...
Merck provides update on IMPROVE-IT Trial
28 March 2012 | By Merck
The DSMB of the IMPROVE-IT trial has completed the second pre-specified interim efficacy analysis of the study...
Merck appoints Michael J. Holston as Chief Ethics and Compliance Officer
28 March 2012 | By Merck
Long-time Merck and Schering-Plough Executive Richard S. Bowles to retire...
Novartis launches the CCLE to catalogue world’s cancer cell lines
28 March 2012 | By Novartis
Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information...
Novasep opens new 2,000 m2 expanded Shanghai facilities to meet increasing East Asia demand
27 March 2012 | By Andrew Lloyd & Associates
Novasep announces the opening of a new 2,000 m2 facility in Shanghai Pudong district...
Biomarker specialist Activiomics appoints Dr Trevor Nicholls as Non-Executive Chairman
27 March 2012 | By College Hill
Activiomics Limited., the developer of innovative biomarker technologies has announced the appointment of industry leader Dr Trevor Nicholls to its Board as Non-Executive Chairman.
US court denies preliminary injunction application against the FDA
26 March 2012 | By AstraZeneca
The US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit...
Sanofi and Regeneron report Phase 2 data for potential first-in-class lipid-lowering PCSK9 antibody
26 March 2012 | By Sanofi
Data from two Phase 2 trials announced...
Teva announces FDA approval of QNASLTM
26 March 2012 | By Teva Pharmaceutical Industries Ltd
New treatment with “dry” mode of delivery seeks to address unmet needs of seasonal and perennial allergy sufferers...
Amgen’s PCSK9 Inhibitor reduced LDL cholesterol up to 81 percent in Phase 1b study
25 March 2012 | By Amgen
Robust AMG 145 Phase 2 program expected to deliver results in 2012...
In TRA-2P Study, adding Merck’s vorapaxar to standard of care significantly reduced the risk of cardiovascular events
24 March 2012 | By Merck
Results from TRA-2P study - published...
GSK and Theravance announce completion of the Relovair™* registrational programme
23 March 2012 | By GlaxoSmithKline
COPD and asthma regulatory plans remain on track for submission from mid-2012...
BYETTA® approved for use with basal insulin in Europe
23 March 2012 | By Amylin Pharmaceuticals, Inc.
Patients in pivotal study achieved better glycemic control overall and after meals...
Catalent extends development and analytical solutions capabilities in Swindon, UK
22 March 2012 | By Catalent Pharma Solutions
Catalent Pharma Solutions announces the completion of new Development and Analytical Solutions’ laboratories at its facility in Swindon, UK.
